Advertising of prescription-only medicines to the public: Does evidence of benefit counterbalance harm?

Annual Review of Public Health

Volumn 33, Issue , 2012, Pages 259-277

  Mintzes, Barbara ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Direct to consumer advertising; Drug safety; Pharmaceutical marketing; Prescribing appropriateness; Prescription drugs

Indexed keywords

ROFECOXIB;

BEHAVIORAL RESEARCH; COST BENEFIT ANALYSIS; DRUG MARKETING; DRUG USE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH INSURANCE; HEALTH STATUS; HUMAN; MEDICAL DECISION MAKING; PATIENT ATTITUDE; PATIENT COMPLIANCE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

ADVERTISING AS TOPIC; DRUG UTILIZATION; EVIDENCE-BASED MEDICINE; HUMANS; LEGISLATION, DRUG; PRESCRIPTION DRUGS; RISK ASSESSMENT;

EID: 84861417548     PISSN: 01637525     EISSN: 15452093     Source Type: Book Series    
DOI: 10.1146/annurev-publhealth-031811-124540     Document Type: Review

References (114)

1. Abramson J, Wright JM. 2007. Are lipid lowering guidelines evidence based? Lancet 369:168-69
2. Aikin KJ, Swasy JL, Braman AC. 2004. Patient and physician attitudes and behaviors associated with DTCA promotion of prescription drugs\summary of FDA survey research results. US Food Drug Admin. Nov. 19
3. An S. 2008. Antidepressant direct-to-consumer advertising and social perception of the prevalence of depression: application of the availability heuristic. Health Commun. 23:6499-505
4. Angell M. 2011. The epidemic of mental illness: why? N. Y. Rev. Books 58(11)1-3. Available at: http://www.nybooks.com/articles/archives/2011/jun/23/ epidemic-mental-illness-why/
5. Arnold M. 2006. The science of DTC. Med. Mark. Media April, pp. 39-45
6. Astra Zeneca. 2007. Annual report and form 20-F information. http://www.astrazeneca-annualreports.com/2007/our-performance/ therapy-area-review/gastrointestinal-medicines/financial-performance.asp
7. Auton F. 2009. The case for advertising pharmaceuticals direct to consumers. Future Med. Chem. 1(4):587-92
8. Avery R, Kenkel D, Lillard DR, Mathios A. 2007. Private profits and public health: Does advertising of smoking cessation products encourage smokers to quit? J. Polit. Econ. 115:447-81
9. Avery RJ, Kenkel D, Lillard DR, Mathios A, Wang H. 2008. Health disparities and direct-to-consumer advertising of pharmaceutical products. Adv. Health Econ. Health Serv. Res. 19:71-94
10. Basara LR. 1992. Direct-to-consumer advertising: today's issues and tomorrow's outlook. J. Drug Issues 22(2):317-30
11. Bell RA, Kravitz RL, Wilkes MS. 2000. Direct-to-consumer prescription drug advertising, 1989-1998: a content analysis of conditions, targets, inducements and appeals. J. Fam. Pract. 49(4):329-35
12. Bell RA, Wilkes MS, Kravitz RL. 2000. The educational value of consumer-targeted prescription drug print advertising. J. Fam. Pract. 49(12):1092-98
13. Block A. 2007. Costs and benefits of direct-to-consumer advertising: the case of depression. Pharmacoeconomics 25(6):511-21
14. Bradford WD, Kleit AN, Nietert PJ, Ornstein S. 2006. Effects of direct-to-consumer advertising of hydroxymethylglutaryl coenzyme A reductase inhibitors on attainment of LDL-C doals. Clin. Ther. 28(12):2105-18
15. Bradford WD, Kleit AN, Nietert PJ, Ornstein S. 2010. The effect of direct-to-consumer television advertising on the timing of treatment. Econ. Inq. 48:306-22
16. Brownfield ED, Berhardt JM, Phan JL, Williams MW, Parker RM. 2004. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. J. Health Commun. 9:491-97
17. Calfee JE, Winston C, Stempski R. 2002. Direct-to-consumer advertising and the demand for cholesterol-reducing drugs. J. Law Econ. 45:673-90
18. Campbell S. 2011. Potential Effects of a Ban on Direct-to-Consumer Advertising of New Prescription Drugs. Econ. Budget Issue Brief. Washington, DC: US Congr. Budget Off. http://www.cbo.gov/ftpdocs/121xx/doc12164/5-25- PrescriptionDrugAdvertising.pdf
19. Comm. Assess. U.S. Drug Saf. Syst. 2007. The Future of Drug Safety: Promoting and Protecting the Health of the Public. Washington, DC: Natl. Acad. Press
20. Correa-de-Araujo R. 2005. Improving the use and safety of medications in women through sex/gender and race/ethnicity analysis: introduction. J. Women's Health 14:12-15
21. Curry TJ, Jarosch J, Pacholok S. 2005. Are direct to consumer advertisements of prescription drugs educational?: Comparing 1992 to 2002. J. Drug Educ. 35:217-332
22. Dai C, Stafford RS, Alexander C. 2005. National trends in cyclooxenase-2 inhibitor use since market release. Nonselective diffusion of a selectively cost-effective innovation. Arch. Intern. Med. 165:171-77
23. Davis JJ. 2000. Riskier than we think? The relationship between risk statement completeness and perceptions of direct to consumer advertised prescription drugs. J. Health Commun. 5:349-69
24. Davis JJ, Cross E, Crowley J. 2007. Pharmaceutical websites and communication of risk information. J. Health Commun. 12:29-39
25. Donohue JM, Berndt ER, Rosenthal M, Epstein AM, Frank RG. 2004. Effects of pharmaceutical promotion on adherence to treatment guidelines for depression. Med. Care 42:1176-85
26. Donohue JM, Cevasco M, Rosenthal MB. 2007. A decade of direct-to-consumer advertising of prescription drugs. N. Engl. J. Med. 357:673-81
27. Dormuth CR, Patrick AR, Shrank WH, Wright JM, Glynn RJ, et al. 2009. Statin adherence and risks of accidents: a cautionary tale. Circulation 119:2051-57
28. Dorn SD, Farley JF, Hansen RA, Shah ND, Sandler RS. 2009. Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses and prescriptions. Gastroenterology 137:518-24
29. Epstein RM, Shields CG, Franks P, Meldrum SC, Feldman M, Kravitz RL. 2007. Exploring and validating patient concerns: relation to prescribing for depression. Ann. Fam. Med. 5:21-28
30. Eur. Med. Agency. 2010. Questions and answers concerning the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim). 23 September 2010. EMA/CHMP/586211/2010. http://www.ema.europa.eu/docs/en-GB/ document-library/Medicine-QA/2010/09/WC500097003.pdf
31. Findlay S. 2001. Prescription Drugs and Mass Media Advertising, 2000. Washington, DC: Natl. Inst. Health Care Manag. http://nihcm.org/pdf/ DTCbrief2001.pdf
32. Fournier JC, DeRubies JR, Hollon SD, Dimidjian S, Amsterdam JD, et al. 2010. Antidepressant drug effects and depression severity. A patient-level meta-analysis JAMA 303(1):47-53
33. Frosch DL, Grande D, Tarn DM, Kravitz RL. 2010. A decade of controversy: balancing policy with evidence in the regulation of prescription drug advertising. Am. J. Public Health 100:24-32
34. Frosch DL, Krueger PM, Hornik RC, Cronholm PF, Barg FK. 2007. Creating demand for prescription drugs: a content analysis of television direct-to-consumer advertising. Ann. Fam. Med. 5(1):6-13
35. Gagnon MA, Lexchin J. 2008. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med. 5(1):e1
36. Gahart MT, Duhamel LM, Dievler A, Price R. 2003. Examining the FDA's oversight of direct-to-consumer advertising. Health Aff. W3:120-22
37. Gardner DM, Mintzes B, Ostry A. 2003. Direct-to-consumer prescription drug advertising in Canada: permission by default? Can. Med. Assoc. J. 169:425-27
38. Gascoigne D. 2004. DTC at the cross roads: a "direct" hit..or miss? Perspectives and prescriptives for enhanced ROI. IMS Issues Insights, 1-6. 04080-A
39. Gilbody S, Wilson P, Watt I. 2005. Benefits and harms of direct to consumer advertising: a systematic review. Qual. Saf. Health Care 14:246-50
40. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, et al. 2005. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxynegase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475-81
41. Greene JA, Herzberg D. 2010. Hidden in plain sight. Marketing prescription drugs to consumers in the twentieth century. Am. J. Public Health 100:793-803
42. Grenard JL, Uy V, Pagan JA, Frosch DL. 2010. Seniors' perceptions of prescription drug advertising: a pilot study of the potential impact on informed decision making. Patient Educ. Couns. 85(1):79-84
43. Grow JM, Park JS, Han X. 2006. "Your Life is Waiting!" Symbolic Meanings in direct-to-consumer antidepressant advertising. J. Commun. Inq. 30:163-88
44. Hansen RA, Chen S-Y, Gaynes BN, Maciejewski ML. 2010. Relationship of pharmaceutical promotion to antidepressant switching and adherence: a retrospective cohort study. Psychiatr. Serv. 61:1232-38
45. Hansen RA, Schommer JC, Cline RR, Hadsall RS, Schondelmeyer SW, Nyman JA. 2005. Theassociation of consumer cost-sharing and direct-to-consumer advertising with prescription drug use. Res. Soc. Admin. Pharm. 1:139-57
46. Hansen RA, Shaheen NJ, Schommer JC. 2005. Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising. Clin. Ther. 27:1478-87
47. Hausken AM, Skurtveit S, Rosvold EO, Bramness JG, Furu K. 2007. Psychotropic drug use among persons with mental distress symptoms: a population-based study in Norway. Scand. J. Public Health 35:356-64
48. Heinrich J. 2002. Prescription Drugs. FDA Oversight of Direct-to-Consumer Advertising Has Limitations. Rep. Congr. Req. GAO-03-177. Washington, DC: US Gen. Account. Off. http://www.gao.gov/new.items/d03177.pdf
49. Herxheimer A. 1998. Many NSAID users who bleed don't know when to stop. BMJ 316:492
50. Hoek J. 2007. Consumer response to DTCA. BMJ Nov 10, 2007. Rapid response to: Toop L, Mangin D. 2007. Direct to consumer advertising: industry funded patient information and the slippery slope to New Zealand. BMJ 335:694-95
51. Huh J, Cude BJ. 2004. Is the information "fair and balanced" in direct-to-consumer prescription drug websites? J. Health Commun. 9:529-40
52. Iizuka T, Jin GZ. 2005. Drug Advertising and Health Habit. NBER Work. Pap. 11770. Cambridge, MA: Natl. Bur. Econ. Res. http://www.nber.org/papers/ w11770
53. Iizuka T. 2004. What explains the use of direct-to-consumer advertising of prescription drugs? J. Ind. Econ. 52(3):349-79
54. Iizuka T, Jin GZ. 2005. The effect of prescription drug advertising on doctor visits. J. Econ. Manag. Strategy 14:701-27
55. IMS Health Inc. 2007. IMS Health. Total US promotional spend by type, 2007. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/ StaticFile/Top-Line-Data/PromotionalSpendChartWebsite.pdf
56. Jackevius CA, Tu JV, Ross JS, Ko DT, Krumholz HM. 2008. Use of ezetimibe in the US and Canada. N. Engl. J. Med. 358:1819-28
57. Josefson D. 2001. FDA Warning to Manufacturers of AIDS Drugs. BMJ 322:1143
58. Jureidini J, Mintzes B, Raven M. 2008. Does direct-to-consumer advertising of antidepressants lead to a net social benefit? Pharmacoeconomics 26:557-66
59. Kantar Media. 2009-2011. Pharmaceutical spending. Ad$pender Database. January-December 2009; all media. McGill Libr. Available at: http://www.mcgill.ca/library/
60. Kelly P. 2004. DTC advertising's benefits far outweigh its imperfections. Health Aff. doi: 10.1377/hlthaff.W4.246
61. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, et al. 2003. The epidemiology of major depressive disorder: results from the national comorbidity study replication (NCS-R). JAMA 289:3095-105
62. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. 2008. Initial severity and antidepressant benefits: a meta-analysis of trials submitted to the US Food and Drug Administration. PLoS Med. 5(2):e45
63. Klausner JD, Kim A, Kent C. 2002. Are HIV drug advertisements contributing to increases in risk behavior among men in San Francisco, 2001? AIDS 6(17):2349-50
64. Kravitz RL, Epistein RM, Feldman MD, Franz CE, Azari R, et al. 2005. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomised controlled trial. JAMA 293:1995-2002
65. Lacasse JR, Leo J. 2005. Serotonin and depression: a disconnect between the advertisements and the scientific literature. PLoS Med. 2(12):e392
66. Law M, Majumdar SR, Soumerai SB. 2008. Effect of illicit direct to consumer 1 advertising on use of etanercept, mometasone, and tegaserod in Canada. BMJ 337:a1055, pp. 1-7
67. Law MR, Soumerai SB, Adams AS, Majumdar S.R. 2009. Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid. Arch. Intern. Med. 169:1969-74
68. Lee D, Begley CE. 2010. Racial and ethnic disparities in response to direct-to-consumer advertising. Am. J. Health Syst. 67:1185-90
69. Lyles A. 2002. Direct marketing of pharmaceuticals to consumers. Annu. Rev. Public Health 23:73-91
70. Macias W, Stavchansky Lewis L. 2006. How well do direct-to-consumer (DTC) prescription drug Web sites meet FDA guidelines and public policy concerns? Health Market. Q. 22:4, 45-71
71. Mamdani M, Juurlink DN, Kopp A, Naglie G, Austin PC, Laupacis A. 2004. Gastrointestinal bleeding after the introduction of Cox 2 inhibitors: ecological study. BMJ 328:1415-16
72. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, et al. 2005. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 330:389-95
73. Mintzes B. 2008. Direct to consumer advertising of prescription drugs. Even attenuated forms such as cross border advertising can cause harm. BMJ 337:a985:526-27
74. Mintzes B, Barer ML, Kravitz RL, Bassett K, Lexchin J, et al. 2003. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Can. Med. Assoc J. 169(5):405-12
75. Mintzes B, Morgan S, Wright JM. 2009. Twelve years' experience with direct-to-consumer advertising of prescription drugs in Canada: a cautionary tale. PLoS ONE 4(5):e5699
76. Mitchell AJ, Vaze A, Rao S. 2009. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 374:609-19
77. Nielsen Media. 2009. Top 10 categories by ad spending. http://www.marketingcharts.com/wp/wp-content/uploads/2010/01/ nielsen-top-10-product-categories-ad-spending-q3-2009.jpg
78. Norey E, Simone TM, Mousa SA. 2008. The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand. Appl. Health Econ. Health Policy 6:93-102
79. Norris P, Nelson L, Ling KL, Skellett L, Hoo J, et al. 2005. Advertising of medicines on New Zealand television. N. Z. Med. J. 118(1215):1-8
80. Palumbo FB, Mullins CD. 2002. The development of direct-to-consumer prescription drug advertising regulation. Food Drug Law J. 57:423-43
81. Parnes B, Smith PC, Gilroy C, Quintela J, Emsermann CB, et al. 2009. Lack of impact of direct-to-consumer advertising on the physician-patient encounter in primary care: a SNOCAP report. Ann. Fam. Med. 7:41-46, 870
82. Patten SB. 2004. The impact of antidepressant treatment on population health: synthesis of data from two national data sources in Canada. Popul. Health Metric 2(1):9
83. Payton AR, Thoits PA. 2011. Medicalization, direct-to-consumer advertising, and mental illness stigma. Soc. Ment. Health 1:55-70
84. Peppin P, Carty E. 2001. Semiotics, stereotypes and women's health: signifying inequality in drug advertising. Can. J. Women Law 13:326-30
85. Pescosolido BA, Martin JK, Long JS, Medina TR, Phelan JC, Link BG. 2010. "A disease like any other?" A decade of change in public reactions to schizophrenia, depression and alcohol dependence. Am. J. Psychiatry 167:1321-30
86. Pfizer. 2011. Lipitor (atorvastatin) advertisement. New Yorker Mag. March 7, p. P25
87. PhRMA. 2009. Guiding principles: direct to consumer advertising. http://www.phrma.org/about/principles-guidelines/direct-consumer-advertising
88. Prescrire. 2011. New drugs and indications in 2010: inadequate assessment; patients at risk. Prescrire Int. 20(115):105-10
89. Prev. Mag. 1998. National Survey of Consumer Reactions to Direct-to-Consumer Advertising. Emmaus, PA: Rodale
90. Prev. Mag. 1999. Year Two: A National Survey of Consumer Reactions to Direct-to-Consumer Advertising. Emmaus, PA: Rodale
91. Richards T. 2008. Purely medicinal? BMJ 336:693
92. Rosenthal MB, Berndt ER, Donohue JM, Epstein AM, Frank R. 2003. Demand effects of recent changes in prescription drug promotion. Forum Health Econ. Policy 6(2):1-26
93. Rosenthal MB, Berndt ER, Donohue JM, Frank RG, Epstein AM. 2002. Promotion of prescription drugs to consumers. N. Engl. J. Med. 346:498-505
94. Schwartz LM, Woloshin S, Welch HG. 2009. Using a drug facts box to communicate drug benefits and harms. Two randomized trials. Ann. Intern. Med. 150:516-27
95. Spence MM, Teleki SS, Cheetham C, Schweitzer SO, Millares M. 2005. Direct-to-consumer advertising of Cox 2 inhibitors. Effects on appropriateness of prescribing. Med. Care Res. Rev. 62:544-59
96. Tentler A, Silberman J, Paterniti DA, Kravitz RL, Epstein RM. 2007. Factors affecting physicians' responses to patients' requests for antidepressants: focus group study. J. Gen. Intern. Med. 23:51-57
97. Therapeutics Initiative. 2002. Do single stereoisomers provide value? Ther. Lett. 45. http://www.ti.ubc.ca/sites/ti.ubc.ca/files/45.pdf
98. 't Jong GW, Stricker BHC, Sturkenboom MC. 2004. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ 328, 931
99. Toop L, Mangin D. 2007. Industry funded patient information and the slippery slope to New Zealand. BMJ 335:694-95
100. Toop L, Richards D, Dowell T, Tilyard M, Fraser T, Arroll B. 2003. Direct-to-Consumer Advertising of Prescription Drugs in New Zealand: For Health or For Profit? Report to the Minister of Health Supporting the Case for a Ban of DTCA. Dunedin, NZ: Univ. Otago
101. Topol EJ. 2004. Failing the public health\rofecoxib, Merck and the FDA. N. Engl. J. Med. 351:1707-9
102. U.S. Food Drug Admin. 2007. Public health advisory. Tegaserod maleate (marketed as Zelnorm). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051284. htm
103. U.S. Food Drug Admin. 2009. Guidance for Industry: Presenting Risk Information in Prescription Drug and Medical Device Promotion. Rockville, MD: US Dep. Health Hum. Serv.
104. U.S. Gen. Account. Off. 2001. Drug Safety: Most Drugs Withdrawn in Recent Years Had Greater Health Risks for Women. GAO-01-286R. Washington, DC: US Gen. Account. Off.
105. U.S. Gen. Account. Off. 2006. Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising. GAO-07-54. Washington, DC: US Gen. Account. Off.
106. U.S. Gen. Account. Off. 2008. Prescription Drugs. Trends in FDA's Oversight of Direct-to-Consumer Advertising. GAO-08-758T. Washington, DC: US Gen. Account. Off.
107. Van den Engh M, Bonertz B. 2010. The effects of direct-to-consumer advertising on patients in a Northern Canadian community: a cross-sectional survey. Can. Pharm. J. 143:126-33
108. Vitry A, Mintzes B, Lexchin J. 2007. Direct-to-consumer advertising policy in Australia: realism in whose interests? Intern. Med. J. 37(9):665-66
109. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman A, Leitman M. 2003. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff. W382
110. Weppner WG, Hollon MF, Chew LD, Larson EB. 2009. Direct-to-consumer offers for free and discounted medications on the Internet: a content analysis of "e-samples". Arch. Intern. Med. 169:2024-30
111. Wijesinghe PR, Norris P. 2008. Increased advertising of medicines on New Zealand television since 2001. N. Z. Med. J. 121(1271):121-22
112. Wosinska M. 2005. Direct-to-consumer advertising and drug therapy compliance. J. Market. Res. 42(3):323-33
113. Yang Y, Gourley DR, Gourley GA, Faris RJ, Womeodu RJ, et al. 2010. African American patients' attitudes towards proactive health behaviors after exposure to direct-to-consumer advertising. J. Natl. Med. Assoc. 102:408-15
114. Zachry WM, Shepherd MD, Hinich MJ, Wilson JP, Brown CM, Lawson KA. 2002. Relationship between direct-to-consumer advertising and physician diagnosis and prescribing. Am. J. Health Syst. Pharm. 59:42-49